Moderna’s Cancer Vaccine Shows Promise | Chattanooga News

Moderna’s stock surged over 100% after breakthrough early data showed its personalized cancer vaccine, intismeran, combined with Merck’s Keytruda, significantly outperformed Keytruda alone in melanoma patients—keeping tumors at bay longer and sparking huge investor excitement for the future of precision oncology. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/939be3151d4cda79